Thrivent Financial for Lutherans Increases Stake in RxSight, Inc. (NASDAQ:RXST)

Thrivent Financial for Lutherans increased its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 53.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 352,626 shares of the company’s stock after buying an additional 122,989 shares during the period. Thrivent Financial for Lutherans owned about 0.88% of RxSight worth $12,124,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in RXST. Geode Capital Management LLC grew its holdings in RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after acquiring an additional 122,775 shares in the last quarter. Barclays PLC grew its holdings in RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock worth $2,906,000 after acquiring an additional 46,783 shares in the last quarter. State Street Corp grew its holdings in RxSight by 8.3% during the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after acquiring an additional 62,349 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in RxSight by 28.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company’s stock worth $14,104,000 after acquiring an additional 62,507 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in RxSight during the 3rd quarter worth approximately $605,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $24.84 on Friday. The stock has a market cap of $1.01 billion, a P/E ratio of -29.93 and a beta of 1.22. The firm has a fifty day moving average price of $29.63 and a 200 day moving average price of $40.05. RxSight, Inc. has a 1-year low of $24.09 and a 1-year high of $66.54.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). The business had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Sell-side analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RXST shares. Bank of America lowered their price target on shares of RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday. UBS Group started coverage on shares of RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price target for the company. Wells Fargo & Company lowered their target price on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lowered their target price on shares of RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a report on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.33.

Insider Buying and Selling

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jesse Anderson Corley acquired 1,443 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were purchased at an average price of $31.18 per share, with a total value of $44,992.74. Following the transaction, the director now owns 1,443 shares in the company, valued at $44,992.74. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 9.36% of the stock is owned by company insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.